Psilocybin-facilitated Treatment for Chronic Pain
RecruitingEarly phase 1NCT05068791
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The primary purpose of this study is to preliminarily estimate the efficacy of psilocybin-facilitated treatment for fibromyalgia. Investigators will assess the impact of psilocybin-facilitated treatment on pain, fatigue, and other fibromyalgia symptoms, in addition to the level of functioning and quality of life. Investigators will also evaluate potential mediators of treatment (e.g., treatment expectations, pain characteristics, personality, beliefs/cognitions, emotions). Investigators hypothesize psilocybin treatment will significantly reduce symptom severity in fibromyalgia patients.
Study details
- Official title
- Psilocybin-facilitated Treatment for Chronic Pain
- Conditions
- Fibromyalgia, Primary
- Interventions
- Drug: Psilocybin
- Drug: Dextromethorphan
- Sponsor
- University of Alabama at Birmingham
- Start date
- 2023-11-01
- Primary completion
- 2026-12-31
- Sex
- Female
- Age range
- from 25 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- United States
- Total sites listed
- 1
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Female age 25-65; 2. Widespread musculoskeletal pain for ≥12 months; 3. Symptoms meeting the American College of Rheumatology (ACR) 2016 revisions to the 2010/2011 Fibromyalgia Diagnostic Criteria; 4. Participant completes daily report during baseline period (at least 80% completion rate); 5. Able to attend UAB for all scheduled appointments; 6. Ability to read/write in English; 7. No prior hallucinogen use or it will have been at least 3 years since last use of a hallucinogen; 8. Availability of a friend or family member into whose care the participant can be released (a key responsibility includes driving participants home) following their drug administration session; 9. A current average daily pain score of at least 5 on a 0-10 scale; 10. Discontinuation of exclusionary medication occurring at least two weeks and for at least 5 half-lives, whichever is longer, prior to drug administration day. Exclusion Criteria: 1. Males; 2. Use of opioid medications in the last 60 days; 3. Regular use of any anti-inflammatory medication (e.g., aspirin, ibuprofen, naproxen); 4. Use of blood thinning medication; 5. Use of tricyclic antidepressants, lithium, SSRIs, MAOIs, St. John's Wort, 5-hydroxytryptophan (5-HT), haloperidol, or other antipsychotic medications, mood stabilizers, or medications with serotonin activity; 6. Daily consumption of grapefruit juice; 7. Febrile illness or use of antibiotics in the 4 weeks before study commencement; 8. Planned surgery or procedures during the study period, or operated on in the 4 weeks prior to study commencement; 9. Planning to move from the Birmingham area in the next 6 months; 10. Planned vaccination during the study period, or vaccinated in the 4 weeks before study commencement; 11. Current participation in another treatment trial; 12. Pregnant or planning to become pregnant within 6 months, or currently breastfeeding; 13. Significant psychological comorbidity that in the discretion of the investigator compromises study integrity (i.e., presence of a current, clinically significant, untreated or unstable psychiatric condition) and/or a baseline HADS depression subscale score of ≥16; 14. Current or past history of any psychotic disorders; 15. Current or past history of bipolar I or II disorder; 16. First or second-degree relatives with any psychotic disorders, or bipolar I or II disorders; 17. Current suicidal or homicidal ideation (assessed using Columbia-Suicide Severity Rating Scale at each visit);…
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT05068791